Global Patent Index - EP 0759782 A1

EP 0759782 A1 19970305 - NEW METHODS AND COMPOUNDS FOR THE SELECTIVE MODULATION OF ANTIGEN-SPECIFIC T-CELL RESPONSIVENESS

Title (en)

NEW METHODS AND COMPOUNDS FOR THE SELECTIVE MODULATION OF ANTIGEN-SPECIFIC T-CELL RESPONSIVENESS

Title (de)

Verfahren und Verbindungen zur selektiven Modulatio9n des antigenspezifischenT - Zelltreaktorvermögens

Title (fr)

NOUVEAUX PROCEDES ET COMPOSES DESTINES A LA MODULATION SELECTIVE DE LA REACTION DES LYMPHOCYTES T SPECIFIQUES D'UN L'ANTIGENE

Publication

EP 0759782 A1 19970305 (EN)

Application

EP 95921760 A 19950526

Priority

  • EP 95921760 A 19950526
  • EP 9502012 W 19950526
  • EP 94870088 A 19940526

Abstract (en)

[origin: WO9532734A1] The present invention relates to new Fc gamma RII bridging compositions for impairing the capacity of antigen presenting cells (APCs) to stimulate the activation of antigen-specific T-cells, resulting in modulation of antigen-specific T-cell responsiveness. More particularly, said Fc gamma RII bridging agents are chosen from the group consisting of: aggregated human IgG molecules; aggregated Fc fragments of human IgG molecules; a bivalent monoclonal antibody to the Fc gamma RII; a multivalent monoclonal antibody to the Fc gamma RII; a functionally active fragment of said bivalent or multivalent monoclonal antibody; a recombinant fusion protein of 2 or more human IgG Fc parts; liposome vesicles comprising any of the foregoing, provided that said Fc gamma RII composition prevents the expression of the co-stimulatory molecules B7-1/2 and/or down modulates the ICAM-3 molecule expression by these professional APCs. The present invention also relates to prophylactic and therapeutic methods and compositions to prevent or treat the rejection of solid organs, tissues and cells after transplantation; for inducing T-cell anergy or T-cell tolerance; for treating allergic diseases; or for the treatment of autoimmune diseases. The present invention also relates to Fc gamma RII bridged professional APCs prepared by bridging APCs with an Fc gamma RII bridging agent according to the present invention.

IPC 1-7

A61K 39/395; A61K 35/14; A61K 9/127; C12N 5/08; G01N 33/53

IPC 8 full level

A61K 9/127 (2006.01); A61K 35/14 (2006.01); A61K 39/395 (2006.01); C07K 14/735 (2006.01); C07K 16/06 (2006.01); C07K 16/28 (2006.01); C12N 5/08 (2006.01); G01N 33/53 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC (source: EP)

C07K 14/70535 (2013.01); C07K 16/065 (2013.01); C07K 16/283 (2013.01); A61K 38/00 (2013.01); A61K 2039/5154 (2013.01)

Citation (search report)

See references of WO 9532734A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9532734 A1 19951207; AU 2670995 A 19951221; CA 2188812 A1 19951207; EP 0759782 A1 19970305

DOCDB simple family (application)

EP 9502012 W 19950526; AU 2670995 A 19950526; CA 2188812 A 19950526; EP 95921760 A 19950526